Two Breast-Cancer Drugs, Two Treatment Clocks

Imagine your breast cancer treatment is working. Scans look stable. But a routine blood draw reveals something troubling: the tumour's DNA, circulating in your bloodstream, carries a new mutation that will eventually make your current therapy useless. Should your doctor switch treatment now, before scans show any change? Or wait until the disease visibly worsens?

That question separates two oral medicines approved months apart in the US. Both target the oestrogen receptor in cancers that have developed ESR1 mutations, a genetic change that lets tumours keep growing even after hormone-blocking therapy. Both select patients using blood tests that detect those mutations. But camizestrant and vepdegestrant arrive at different moments in a patient's treatment and work through different molecular machinery.

Acting on a warning versus treating a failure

Camizestrant, branded Etcamah and developed by AstraZeneca, is designed for patients whose current treatment still appears to be working. Its pivotal trial, SERENA-6, enrolled patients on first-line hormone therapy combined with a companion drug called a CDK4/6 inhibitor (medicines that block a protein cancer cells need to divide). Every two to three months, patients had blood drawn. When a plasma test detected an ESR1 mutation, 315 patients were randomised: some swapped their hormone therapy for camizestrant while keeping their CDK4/6 inhibitor, others continued as before (NEJM).

Median progression-free survival, the time before scans showed disease worsening, was 16.0 months with camizestrant versus 9.2 months with continued hormone therapy. Quality-of-life deterioration was also delayed: 23.0 months versus 6.4 months (NEJM). The FDA granted accelerated approval on 4 September 2026, though its advisory committee had earlier voted 3–6 against, citing concern about switching treatment earlier without proof that it extends life. Overall survival data remain immature (NEJM, FDA meeting record).

Vepdegestrant, branded Veppanu and developed by Arvinas and Pfizer, treats a later situation: patients whose cancer has already progressed after endocrine therapy. In the VERITAC-2 trial of 624 patients, it beat the injectable comparator fulvestrant only in those with confirmed ESR1 mutations, with median progression-free survival of 5.0 months versus 2.1 months. In the full, unselected population, the difference was not statistically significant (NEJM, FDA). The FDA granted regular approval on 1 May 2026, restricted to ESR1-mutated disease.

There has been no head-to-head trial. The drugs occupy different treatment moments, used different comparators and tested different combination strategies. SERENA-6 intervened before visible progression and kept the CDK4/6 inhibitor running; VERITAC-2 treated after failure, as monotherapy (SERENA-6, VERITAC-2).

Two ways to destroy the same receptor

Both drugs bind the oestrogen receptor, change its shape and promote its degradation. The difference is how.

Camizestrant is a SERD, a selective oestrogen-receptor degrader. It locks onto the receptor and destabilises it, accelerating the cell's disposal of the altered protein. This is an oral refinement of what the injectable drug fulvestrant has done for years (camizestrant preclinical paper).

Vepdegestrant belongs to a newer class called PROTACs, molecules engineered with two functional ends connected by a chemical linker. One end grabs the oestrogen receptor; the other recruits a cellular enzyme that tags it for destruction. The cell's protein-recycling machinery then dismantles the tagged receptor. PROTACs are designed to detach afterward and repeat the cycle with fresh targets (Nature Reviews Drug Discovery). Whether that catalytic recycling operates as designed in patients is a class-level question still being studied.

Where European patients stand

The European Commission authorised camizestrant in July 2026 (EMA EPAR). Vepdegestrant has no European authorisation. Yet EU marketing authorisation does not automatically mean patients can get the drug. As of mid-September, searches of German and Polish public databases found no published benefit assessment or reimbursement decision for camizestrant (G-BA, AOTMiT).

Camizestrant's label also requires a validated blood test to detect ESR1 mutations. The SERENA-6 trial screened 3,325 patients with repeated plasma tests to identify those eligible for randomisation (NEJM). Routine surveillance of that kind, with blood draws every two to three months for patients whose treatment is still working, would need dedicated laboratory capacity and funding.

Camizestrant's path forward runs through country-level reimbursement and diagnostic readiness across Europe. Vepdegestrant's starts earlier: it still needs a European marketing authorisation. For camizestrant, the outstanding clinical question is whether acting on a molecular warning, before the cancer visibly worsens, ultimately extends life.